Skip to main content


Log in

Automated in-process characterization and selection of cell-clones for quality and efficient cell manufacturing

  • Short Communication
  • Published:
Cytotechnology Aims and scope Submit manuscript


Delivery of safe, effective and reliable cellular therapies, whether based on mesenchymal stromal cells (MSCs) or induced pluripotent stem cells (iPSCs), demand standardization of cell culture protocols. There is a need to develop automation platform that enables the users to generate culture expanded human cell populations that improves the quality and reduces batch-to-batch variation with respect to biological potential. Cell X™ robot was designed to address these current challenges in the cell fabrication industry. It utilizes non-invasive large field of view quantitative image analysis to guide an automated process of targeted “biopsy” (cells or media), “picking” (selection) of desired cells or colonies, or “weeding” (removal) of undesired cells, thus providing an unprecedented ability to acquire quantitative measurement in a complex heterogeneous cell environment “in process” and then to act on those measurements to define highly reproducible methods for cell and colony “management” based on application specific critical quality attributes to improve the quality of the manufactured cell lines and cell products.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3
Fig. 4


Download references


Cleveland Clinic and Parker Hannifin have collaborated to create Cell X™ Platform. Biospherix (Lacona, New York) provided active support enabling the design of the Cell X™ Work Space, based on the CytoCentric™ principles. iPS-derived cardiomyocytes were studied in collaboration with David Van-Wagoner.

The work was supported by funding from NIH (R21AR067357), Lisa Dean Moseley Foundation and NIH-NCAI (NCAI-17-7-APP-CCF-Muschler) on which GFM is the Principal Investigator.

Author information

Authors and Affiliations


Corresponding author

Correspondence to Venkata P. Mantripragada.

Ethics declarations

Conflict of interests

GFM and KP are named inventors on two issued and one pending patent that have been licensed by Cell X Technologies.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (PPTX 29853 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mantripragada, V.P., Luangphakdy, V., Hittle, B. et al. Automated in-process characterization and selection of cell-clones for quality and efficient cell manufacturing. Cytotechnology 72, 615–627 (2020).

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: